NZ740644A - Glucagon receptor agonists - Google Patents

Glucagon receptor agonists

Info

Publication number
NZ740644A
NZ740644A NZ74064416A NZ74064416A NZ740644A NZ 740644 A NZ740644 A NZ 740644A NZ 74064416 A NZ74064416 A NZ 74064416A NZ 74064416 A NZ74064416 A NZ 74064416A NZ 740644 A NZ740644 A NZ 740644A
Authority
NZ
New Zealand
Prior art keywords
glucagon receptor
glucagon
receptor agonists
aib
ethoxy
Prior art date
Application number
NZ74064416A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Tamer Coskun
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of NZ740644A publication Critical patent/NZ740644A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ74064416A 2015-10-26 2016-10-14 Glucagon receptor agonists NZ740644A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246199P 2015-10-26 2015-10-26
PCT/US2016/056969 WO2017074715A1 (en) 2015-10-26 2016-10-14 Glucagon receptor agonists

Publications (1)

Publication Number Publication Date
NZ740644A true NZ740644A (en) 2019-10-25

Family

ID=57200152

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ74064416A NZ740644A (en) 2015-10-26 2016-10-14 Glucagon receptor agonists

Country Status (25)

Country Link
US (3) US9764004B2 (enExample)
EP (2) EP3368060B1 (enExample)
JP (3) JP6321299B2 (enExample)
KR (1) KR20180053747A (enExample)
CN (2) CN108348583B (enExample)
AR (2) AR106318A1 (enExample)
AU (2) AU2016344433B2 (enExample)
BR (1) BR112018006920A2 (enExample)
CA (2) CA3003242C (enExample)
DK (1) DK3368060T3 (enExample)
EA (2) EA201890676A1 (enExample)
ES (2) ES2747908T3 (enExample)
HR (1) HRP20201353T1 (enExample)
HU (1) HUE050859T2 (enExample)
IL (1) IL258092A (enExample)
LT (1) LT3368060T (enExample)
MX (2) MX377610B (enExample)
NZ (1) NZ740644A (enExample)
PL (2) PL3368061T3 (enExample)
PT (2) PT3368061T (enExample)
RS (1) RS60567B1 (enExample)
SI (1) SI3368060T1 (enExample)
TW (1) TWI622596B (enExample)
WO (2) WO2017074714A1 (enExample)
ZA (2) ZA201801756B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
AU2016378739A1 (en) 2015-12-23 2018-07-05 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
EP4353250A3 (en) * 2017-06-21 2024-06-19 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
EP3664833B1 (en) * 2017-08-09 2023-05-31 Sanofi Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
MY207828A (en) 2017-09-22 2025-03-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
TW202415675A (zh) * 2017-12-21 2024-04-16 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140025A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140021A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
KR102351313B1 (ko) * 2018-07-23 2022-01-17 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
SG11202100116TA (en) * 2018-07-23 2021-02-25 Lilly Co Eli Method of using a gip/glp1 co-agonist for diabetes
JP7684902B2 (ja) * 2018-10-04 2025-05-28 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン及びこれを含む組合せ物の治療学的用途
CA3116271A1 (en) * 2018-10-26 2020-04-30 Novo Nordisk A/S Stable semaglutide compositions and uses thereof
US12257287B2 (en) 2018-11-12 2025-03-25 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Glucagon-derived peptide and use thereof
US20200268835A1 (en) * 2019-02-27 2020-08-27 Novo Nordisk A/S Compounds For Use in NASH
EP3937904A1 (en) * 2019-03-15 2022-01-19 Eli Lilly and Company Preserved formulations
AU2020305592B2 (en) * 2019-06-28 2021-05-13 Hanmi Pharm. Co., Ltd. Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
KR20220143036A (ko) * 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
EP4204440A1 (en) 2020-10-17 2023-07-05 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
JP7604666B2 (ja) 2021-01-20 2024-12-23 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
MX2023013492A (es) 2021-05-13 2024-02-29 Carmot Therapeutics Inc Moduladores de los receptores acoplados a proteinas g.
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
CN120349392A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种gip激动剂化合物
WO2025240560A2 (en) 2024-05-15 2025-11-20 Rose Pharma Inc. Glp-1 formulations and their uses

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004932A (en) 1997-03-06 1999-12-21 Iowa State University Research Foundation, Inc. Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
BRPI0506694A (pt) * 2004-01-08 2007-05-02 Theratechnologies Inc análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
MX2009008241A (es) * 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AR072160A1 (es) * 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
EP2560675A1 (en) * 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
KR20140020851A (ko) 2010-12-22 2014-02-19 마르카디아 바이오테크, 인코퍼레이트 Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
CA2830974A1 (en) 2011-03-28 2012-10-04 Jesper F. Lau Novel glucagon analogues
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
US9944687B2 (en) * 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
US20130316941A1 (en) * 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
EP2844669B1 (en) 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
KR20150039748A (ko) 2012-06-21 2015-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤의 유사체들
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
SG11201500375PA (en) * 2012-07-23 2015-02-27 Zealand Pharma As Glucagon analogues
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
JP6230352B2 (ja) 2013-09-19 2017-11-15 ユニ・チャーム株式会社 動物用排泄物処理材の製造方法および製造装置
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN119119235A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US20150150643A1 (en) * 2013-12-02 2015-06-04 The Johns Hopkins University Personalized computational modeling of atrial fibrosis to guide catheter ablation of atrial fibrillation
WO2015086733A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) * 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
AR098615A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098616A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
JP2017509603A (ja) * 2014-02-18 2017-04-06 ノヴォ ノルディスク アー／エス 安定なグルカゴン類似体及び低血糖症の処置のための使用
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
CN107636009B (zh) 2014-12-30 2021-04-16 韩美药品株式会社 具有改善的稳定性的胰高血糖素衍生物
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
WO2016198604A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
TWI713541B (zh) 2015-06-30 2020-12-21 南韓商韓美藥品股份有限公司 升糖素衍生物及包含該衍生物之長效接合物之組成物
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑

Also Published As

Publication number Publication date
BR112018007225A2 (pt) 2018-10-16
EA038330B1 (ru) 2021-08-10
ES2809548T3 (es) 2021-03-04
AR106325A1 (es) 2018-01-03
WO2017074714A1 (en) 2017-05-04
US9764004B2 (en) 2017-09-19
CA3003242A1 (en) 2017-05-04
BR112018006920A2 (pt) 2018-11-06
CN108135981A (zh) 2018-06-08
US9884093B2 (en) 2018-02-06
EA201890634A1 (ru) 2018-10-31
EP3368060A1 (en) 2018-09-05
CA3003242C (en) 2022-08-09
PL3368060T3 (pl) 2021-01-11
CN108348583A (zh) 2018-07-31
LT3368060T (lt) 2020-08-25
US20180104312A1 (en) 2018-04-19
AU2016344434B2 (en) 2019-06-06
TWI622596B (zh) 2018-05-01
EA201890676A1 (ru) 2019-01-31
HUE050859T2 (hu) 2021-01-28
EP3368061B1 (en) 2019-08-07
PL3368061T3 (pl) 2020-03-31
AU2016344433A1 (en) 2018-04-19
MX2018005132A (es) 2018-06-06
AU2016344434A1 (en) 2018-06-07
ZA201802371B (en) 2020-01-29
TW201726717A (zh) 2017-08-01
PT3368061T (pt) 2019-10-28
MX2018005129A (es) 2018-06-06
DK3368060T3 (da) 2020-08-24
CN108348583B (zh) 2022-06-03
EP3368060B1 (en) 2020-06-24
AR106318A1 (es) 2018-01-03
US20170114115A1 (en) 2017-04-27
JP6354017B2 (ja) 2018-07-11
AU2016344433B2 (en) 2018-12-06
ES2747908T3 (es) 2020-03-12
JP6321299B2 (ja) 2018-05-09
JP2018135346A (ja) 2018-08-30
CA3000538A1 (en) 2017-05-04
WO2017074715A1 (en) 2017-05-04
RS60567B1 (sr) 2020-08-31
US20170112904A1 (en) 2017-04-27
JP2018504376A (ja) 2018-02-15
KR20180053747A (ko) 2018-05-23
JP2018508464A (ja) 2018-03-29
MX377610B (es) 2025-03-10
ZA201801756B (en) 2019-10-30
PT3368060T (pt) 2020-09-01
SI3368060T1 (sl) 2020-08-31
JP7211712B2 (ja) 2023-01-24
CN108135981B (zh) 2022-04-15
HRP20201353T1 (hr) 2020-11-27
EP3368061A1 (en) 2018-09-05
IL258092A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
NZ740644A (en) Glucagon receptor agonists
IL279300A (en) 1-GLP agonist receptors and their use
IL279224A (en) 1-GLP agonist receptors and their use
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
ZA201902950B (en) Acylated glp-1/glp-2 dual agonists
MD3242887T2 (ro) Compuși co-agonişti ai GIP și GLP-1
MX382321B (es) Nuevo polipéptido con afinidad por pd-l1.
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
UA118558C2 (uk) Пептидна сполука
MX388904B (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
MX2019006600A (es) Agonistas duales de glp-1/glp-2.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201491898A1 (ru) Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
EA201070722A1 (ru) Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
MY195657A (en) Liraglutide In Cardiovascular Conditions
MX387920B (es) Peptidos antagonistas de prgc.
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.
EA201100132A1 (ru) Единичная доза ападеносона
PH12016500044A1 (en) Vasopressin-2 receptor agonists

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2022 BY THOMSON REUTERS

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2023 BY THOMSON REUTERS

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2024 BY THOMSON REUTERS

Effective date: 20230904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2026 BY ANAQUA SERVICES

Effective date: 20250924